[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,504,016
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.29
  • Price/Sales 11.04
  • Price/Cash Flow 29.71
  • Price/Book 6.86

Options Overview Details

View History
  • Implied Volatility 35.03% (+0.87%)
  • Historical Volatility 32.15%
  • IV Percentile 69%
  • IV Rank 53.61%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 1) 14.37 (2.89%)
  • Put/Call Vol Ratio 0.69
  • Today's Volume 4,873
  • Volume Avg (30-Day) 2,755
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 47,915
  • Open Int (30-Day) 44,976
  • Expected Range 482.14 to 510.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.25
  • Number of Estimates 6
  • High Estimate $4.47
  • Low Estimate $3.98
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
433.80 +14.45%
on 06/10/26
533.67 -6.96%
on 07/07/26
+50.73 (+11.38%)
since 06/09/26
3-Month
412.27 +20.43%
on 05/05/26
533.67 -6.96%
on 07/07/26
+49.72 (+11.13%)
since 04/09/26
52-Week
362.50 +36.97%
on 08/11/25
533.67 -6.96%
on 07/07/26
+17.54 (+3.66%)
since 07/09/25

Most Recent Stories

More News
1 Momentum Stock to Research Further and 2 Facing Headwinds

1 Momentum Stock to Research Further and 2 Facing Headwinds

HNI : 39.02 (+0.98%)
CALY : 18.47 (+2.21%)
VRTX : 496.50 (-0.39%)
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals...

CRNX : 83.62 (+0.16%)
VRTX : 496.50 (-0.39%)
Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

CRSP : 56.34 (-4.83%)
CRNX : 83.62 (+0.16%)
VRTX : 496.50 (-0.39%)
AI stocks sink and drag markets lower worldwide

The roller-coaster ride for AI stocks snapped back down and dragged Wall Street lower

NVDA : 202.78 (-0.66%)
AAPL : 316.22 (+0.90%)
AVGO : 401.11 (+3.20%)
$SPX : 7,543.64 (+0.81%)
CRNX : 83.62 (+0.16%)
MU : 991.64 (+4.52%)
VRTX : 496.50 (-0.39%)
RIVN : 18.12 (+8.76%)
$IUXX : 29,727.10 (+1.62%)
WULF : 23.20 (+1.62%)
SPCX : 152.16 (+2.60%)
INTC : 112.54 (+2.09%)
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference...

VRTX : 496.50 (-0.39%)
3 Cash-Heavy Stocks with Promising Prospects

3 Cash-Heavy Stocks with Promising Prospects

AMP : 500.16 (+1.95%)
RELY : 23.56 (+1.99%)
VRTX : 496.50 (-0.39%)
Vertex to Acquire Crinetics Pharmaceuticals

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - ...

CRNX : 83.62 (+0.16%)
VRTX : 496.50 (-0.39%)
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately...

VRTX : 496.50 (-0.39%)
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

VRTX : 496.50 (-0.39%)
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

IBB : 197.34 (+0.51%)
VRTX : 496.50 (-0.39%)
GILD : 134.84 (-0.72%)
AMGN : 363.62 (-1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 522.80
2nd Resistance Point 511.79
1st Resistance Point 504.14
Last Price 496.50
1st Support Level 485.48
2nd Support Level 474.47
3rd Support Level 466.82

See More

52-Week High 533.67
Last Price 496.50
Fibonacci 61.8% 468.28
Fibonacci 50% 448.08
Fibonacci 38.2% 427.89
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.